Kiniksa Pharmaceuticals Files $400 Million Mixed Shelf
Kiniksa Pharmaceuticals (KNSA) on Friday filed a registration statement for the potential offering of up to $400 million worth of securities from time to time. The filing covers the potential sale of
Express News | Kiniksa Pharmaceuticals Ltd Files for Mixed Shelf of up to $400 Mln - SEC Filing
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Health care stocks were mixed pre-bell Wednesday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.5% recently. Savara (SVRA) rose past 17% aft
Express News | Kiniksa Pharmaceuticals - Samsung to Perform Tech. Transfer, Process Performance Qualification, Manufacturing & Supply Services for Supply of Arcalyst
Express News | Kiniksa Pharmaceuticals Ltd - Unit Entered Master Services Agreement and Product Specific Agreement With Samsung Biologics Co., Ltd.
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pulls Back 3.9% This Week, but Still Delivers Shareholders Decent 6.4% CAGR Over 5 Years
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. But Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ha
Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative
PDF Version – Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –– American Heart Association to work with champions at 15 healthcare sites to implement i
Express News | Kiniksa Pharmaceuticals - Expects Redomiciliation To Take Effect On Or Around June 27, 2024; Supreme Court Of Bermuda Issued An Order Sanctioning Scheme Of Arrangement Between Company And Its Shareholders
Express News | Kiniksa Pharmaceuticals Ltd - Supreme Court of Bermuda Issued an Order Sanctioning Scheme of Arrangement Between Company and Its Shareholders
Express News | Kiniksa Pharmaceuticals Ltd - Expects Redomiciliation to Take Effect on or Around June 27, 2024
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PDF Version HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman
Sector Spotlight: Orphan Drug Developers With Significant Upside
Market Underestimates Kiniksa Pharmaceuticals' Abiprubart Potential Despite Positive Industry Indicators
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
PDF Version HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of A
Express News | Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $30
Express News | Kiniksa Pharmaceuticals Ltd : JP Morgan Raises Target Price to $30 From $26
Kiniksa Pharmaceuticals (NASDAQ:KNSA): New Drug Treatment Could Have Upside Potential